| Quest Diagnostics, French agency seek to expand breast cancer gene database | |
| | |
|
NEW YORK, April 21 (Reuters) - Quest Diagnostics Inc , the world's largest provider of diagnostic testing services, is working with France's national health agency to build an expanded database for BRCA1 and BRCA2 gene mutations to better determine patient hereditary risks of breast and ovarian cancer. With the broader pool, Quest will also be able to conduct research studies, he said. Fees for access to the database will run from the tens of thousands of dollars to hundreds of thousands of dollars for private laboratories. The number of tests for BRCA1 and BRCA2 mutations has jumped since Angelina Jolie revealed 18 months ago that she had the mutation associated with breast and ovarian cancer. There are some mutations in the BRCA1 and BRCA2 genes that are well recognized as raising the risk of breast and ovarian cancer, but there are thousands of other possible mutations in the genes whose significance remains unknown. In the United States, Myriad Genetics Inc has the longest history of BRCA testing as well as the highest volume of tests. It holds over 90 percent of the market for hereditary cancer testing and has cited its database as a competitive advantage. Myriad had held a patent on BRCA1 and BRCA2 testing, but after the U.S. Supreme Court ruled it invalid, other laboratories entered the market in 2013. In addition to Quest and LabCorp, Invitae Corp, privately held Ambry Genetics and the University of Washington in Seattle offer BRCA1 and BRCA2 testing. (Reporting by Caroline Humer, editing by G Crosse)
|
|
| |
ProfilIndicateurs de MarchéVALEUR : Projets & res.Communiqués de PresseRapport annuelRISQUE : Profile actifsContactez la cie |
Myriad Genetics est une société basée aux Etats-Unis D'Amerique. Myriad Genetics est cotée aux Etats-Unis D'Amerique. Sa capitalisation boursière aujourd'hui est 1,7 milliards US$ (1,6 milliards €). La valeur de son action a atteint son plus bas niveau récent le 29 mai 1998 à 10,00 US$, et son plus haut niveau récent le 17 novembre 2000 à 94,06 US$. Myriad Genetics possède 68 090 000 actions en circulation. |